Cost-effectiveness of once daily GLP-1 receptor agonist lixisenatide compared to bolus insulin both in combination with basal insulin for the treatment of patients with type 2 diabetes in Norway

References

• International Diabetes Federation. IDF Diabetes Atlas. IDF, 2013. Available at: www.idf.org/diabetesatlas [last accessed 17 March 2013]
   Google Scholar
• Strom H, Selmer R, Birkeland KI, et al. No increase in new users of blood glucose-lowering drugs in Norway 2006–2011: a nationwide prescription database study. BMC Public Health 2014;14:520
   Web of Science ®Google Scholar
• Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-12
   PubMed Web of Science ®Google Scholar
• The UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53
   PubMed Web of Science ®Google Scholar
• Zhang P, Zhang X, Brown J, et al. Global healthcare expenditure on diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010;87:293-301
   PubMed Web of Science ®Google Scholar
• Solli O, Jenssen T, Kristiansen IS. Diabetes: cost of illness in Norway. BMC Endocrine Disorders 2010;10:1-8
   Google Scholar
• Health and consumers directorate-general. Estimates of cost of diabetes per year in the European Union and in other European countries. European Commission, 2011. Available at: http://ec.europa.eu/health/major_chronic_diseases/docs/idf_cost_2011.pdf [last accessed 17 March 2013]
   Google Scholar
• Clarke PM, Gray AM, Briggs A, et al. Cost–utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72). Diabetologia 2005;48:868-77
   PubMed Web of Science ®Google Scholar
• Dilla T, Valladares A, Nicolay C, et al. Healthcare costs associated with change in body mass index in patients with type 2 diabetes mellitus in Spain: the ECOBIM study. Appl Health Econ Health Policy 2012;10:417-30
   PubMedGoogle Scholar
• Van NK, Globe D, Ng-Mak D, et al. The association between employee obesity and employer costs: evidence from a panel of U.S. employers. Am J Health Promot 2014;28:277-85
   Google Scholar
• Davis WA, Bruce DG, Davis TM. Economic impact of moderate weight loss in patients with type 2 diabetes: the Fremantle Diabetes Study. Diabet Med 2011;28:1131-5
   Web of Science ®Google Scholar
• Bagust A, Beale S. Modelling EuroQol health-related utility values for diabetic complications from CODE-2 data. Health Econ 2005;14:217-30
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:837-53
   PubMed Web of Science ®Google Scholar
• Wright A, Burden AC, Paisey RB, et al. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). Diabetes Care 2002;25:330-6
   PubMed Web of Science ®Google Scholar
• Heine RJ, Van Gaal LF, Johns D, et al. Exenatide versus insulin glargine in patients with sub-optimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2005;143:559-69
   PubMed Web of Science ®Google Scholar
• Riddle MC, Aronson R, Home P, et al. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L). Diabetes Care 2013;36:2489-96
   PubMed Web of Science ®Google Scholar
• Buse JB, Bergenstal RM, Glass LC, et al. Use of twice-daily exenatide in basal insulin–treated patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med 2011;154:103-12
   PubMed Web of Science ®Google Scholar
• Charbonnel B, Bertolini M, Tinahones FJ, et al. Lixisenatide plus basal insulin in patients with type 2 diabetes mellitus: a meta-analysis. J Diabetes Complications 2014;28:880-6
   PubMed Web of Science ®Google Scholar
• Christensen M, Miossec P, Larsen BD, et al. The design and discovery of lixisenatide for the treatment of type 2 diabetes mellitus. Expert Opin Drug Discov 2014;9:1223-51
   PubMed Web of Science ®Google Scholar
• McEwan P, Foos V, Palmer JL, et al. Validation of the IMS CORE Diabetes Model. Value Health 2014;17:714-24
   PubMed Web of Science ®Google Scholar
• Palmer AJ, Roze S, Valentine WJ, et al. The CORE Diabetes Model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin 2004;20(Suppl 1):5-26
   PubMed Web of Science ®Google Scholar
• Palmer AJ, Roze S, Valentine W, et al. Validation of the CORE Diabetes Model against epidemiological and clinical studies. Curr Med Res Opin 2004;20(Suppl 1):S27-40
   PubMed Web of Science ®Google Scholar
• World Health Organization Regional Office for Europe. European Detailed Mortality Database. WHO, 2014. Available at: http://data.euro.who.int/dmdb/ [Last accessed 25 October 2012]
   Google Scholar
• The Norwegian Renal Registry. Annual Report 2011. NRR, 2011. Available at: http://www.nephro.no/nnr/AARSM2011.pdf [last accessed 17 March 2013]
   Google Scholar
• Jenssen TG, Tonstad S, Claudi T, et al. The gap between guidelines and practice in the treatment of type 2 diabetes a nationwide survey in Norway. Diabetes Res Clin Pract 2008;80:314-20
   PubMed Web of Science ®Google Scholar
• Socialstyrelsen. Diabetesvård Landstingens och kommunernas insatser (diabetes care and local government operations). 2012. http://www.socialstyrelsen.se/publikationer2012/2012-1-2 [last accessed 17 March 2013]
   Google Scholar
• Noklus. Norwegian Quality Improvement of Primary Health Care Laboratories. 2014. Available at: http://www.noklus.no/Diabetesregisterforvoksne/Diabetesregisterforvoksne.aspx [last accessed March 17 2013]
   Google Scholar
• Sundling V, Gulbrandsen P, Jervell J, et al. Care of vision and ocular health in diabetic members of a national diabetes organization: a cross-sectional study. BMC Health Serv Res 2008;8:159
   Google Scholar
• McMullin J, Brozek J, Jaeschke R, et al. Glycemic control in the ICU: a multicenter survey. Intensive Care Med 2004;30:798-803
   Google Scholar
• Lyon KC. The case for evidence in wound care: investigating advanced treatment modalities in healing chronic diabetic lower extremity wounds. J Wound Ostomy Continence Nurs 2008;35:585-90
   Web of Science ®Google Scholar
• Jones LE, Doebbeling CC. Depression screening disparities among veterans with diabetes compared with the general veteran population. Diabetes Care 2007;30:2216-21
   Google Scholar
• Rosenstock J, Ahmann AJ, Colon G, et al. Advancing insulin therapy in type 2 diabetes previously treated with glargine plus oral agents: prandial premixed (insulin lispro protamine suspension/lispro) versus basal/bolus (glargine/lispro) therapy. Diabetes Care 2008;31:20-5
   PubMed Web of Science ®Google Scholar
• Fritsche A, Larbig M, Owens D, et al. Comparison between a basal–bolus and a premixed insulin regimen in individuals with type 2 diabetes – results of the GINGER study. Diabetes Obes Metab 2010;12:115-23
   PubMed Web of Science ®Google Scholar
• Ligthelm RJ, Gylvin T, DeLuzio T, et al. A comparison of twice-daily biphasic insulin aspart 70/30 and once-daily insulin glargine in persons with type 2 diabetes mellitus inadequately controlled on basal insulin and oral therapy: a randomized, open-label study. Endocr Pract 2011;17:41-50
   Google Scholar
• Robbins DC, Beisswenger PJ, Ceriello A, et al. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison. Clin Ther 2007;29:2349-64
   PubMed Web of Science ®Google Scholar
• Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 1997;50:683-91
   PubMed Web of Science ®Google Scholar
• Weinstein MC, O’Brien B, Hornberger J, et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices – Modeling Studies. Value Health 2003;6:9-17
   PubMed Web of Science ®Google Scholar
• Clarke PM, Gray AM, Briggs A, et al. A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologia 2004;47:1747-59
   PubMed Web of Science ®Google Scholar
• World Health Organization. Making choices in health: WHO guide to cost-effectiveness analysis. Geneva: World Health Organization, 2003
   Google Scholar
• Helsedirektoratet. ISF. 2013. Available at: www.helsedirektoratet.no/ [last accessed March 17 2013]
   Google Scholar
• Den Norske legeforeingen. Normaltariffen. Den norske legeforening. 2013. Available at: http://legeforeningen.no/ [last accessed March 17 2013]
   Google Scholar
• Statistics Norway. 2014. Available at: http://www.ssb.no/en/ [last accessed March 17 2013]
   Google Scholar
• Price database. Norwegian Medicines Agency. 2013. Available at: http://www.legemiddelverket.no/Blaa_resept_og_pris/pris-paa-legemidler/maksimalpris/Sider/default.aspx [last accessed March 17 2013]
   Google Scholar
• Raskin P, Gylvin T, Weng W, et al. Comparison of insulin detemir and insulin glargine using a basal–bolus regimen in a randomized, controlled clinical study in patients with type 2 diabetes. Diabetes Metab Res Rev 2009;25:542-8
   PubMed Web of Science ®Google Scholar
• Beaudet A, Clegg JP, Lloyd A. PDB54 systematic literature review of utility values associated with type 2 diabetes-related complications. Value Health 2012;15:A503
   Google Scholar
• Solli O, Stavern K, Kristiansen IS. Health-related quality of life in diabetes: the associations of complications with EQ-5D scores. Health Qual Life Outcomes 2010;8:1-8
   Google Scholar
• Guidelines on how to conduct pharamacoeconomic analyses. Norwegian Medicines Agency. 2012. Available at: http://www.legemiddelverket.no/English/price_and_reimbursement/application_for_reimursement/Lists/PageAttachments/default/NO/Pharmacoeconomic%20guidelines%20-%20Norway.pdf [last accessed March 17 2013]
   Google Scholar
• Eli Lilly and company. Exenatide Once-Weekly (Bydureon) for the Treatment of Type 2 Diabetes. NICE, 2011. Available at: http://www.nice.org.uk/guidance/ta248/documents/diabetes-type-2-exenatide-prolonged-release-appraisal-consultation-manufacturer-submission-from-eli-lilly2 [last accessed 17 March 2013]
   Google Scholar
• Briggs AH, Wonderling DE, Mooney CZ. Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation. Health Econ 1997;6:327-40
   PubMed Web of Science ®Google Scholar
• Ray JA, Boye KS, Yurgin NR, et al. Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes. Curr Med Res Opin 2007;23:609-22
   PubMed Web of Science ®Google Scholar
• Beaudet A, Palmer JL, Timlin L, et al. Cost-utility of exenatide once weekly compared with insulin glargine in patients with type 2 diabetes in the UK. J Med Econ 2011;14:357-66
   PubMedGoogle Scholar
• Klonoff DC, Buse JB, Nielsen LL, et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 2008;24:275-86
   PubMed Web of Science ®Google Scholar
• Meyers JL, Parasuraman S, Bell KF, et al. The high-cost, type 2 diabetes mellitus patient: an analysis of managed care administrative data. Arch Public Health 2014;72:1-12
   Google Scholar
• Raccah D, Lin J, Wang E, et al. Once-daily prandial lixisenatide versus once-daily rapid-acting insulin in patients with type 2 diabetes mellitus insufficiently controlled with basal insulin: analysis of data from five randomized, controlled trials. J Diabetes Complications 2014;28:40-4
   PubMed Web of Science ®Google Scholar
• Jansen JP, Trikalinos T, Cappelleri JC, et al. Indirect treatment comparison/network meta-analysis study questionnaire to assess relevance and credibility to inform health care decision making: an ISPOR-AMCP-NPC Good Practice Task Force report. Value Health 2014;17:157-73
   PubMed Web of Science ®Google Scholar